Abraxane: profile and news

American Pharmaceutical Partners Reiterates 2005 ABRAXANE Revenue ... Feb 9, 2006
Partners, Inc. today reiterated its financial guidance for the 2005 full year ABRAXANE net sales of between $125 - $140 million. The ... - International News Service,

The Abraxane Story: A Nanoparticle Platform Delivers Improved ... Feb 12, 2006
Hawkins, Chief Medical Officer of American BioScience, Inc., in Santa Monica, CA, presented some of the clinical data for Abraxane®, the first approved drug ... - Nanotechwire.com,

American Pharmaceutical Partners Reiterates 2005 ABRAXANE Revenue ... Feb 9, 2006
...(Nasdaq: APPX - News) today reiterated its financial guidance for the 2005 full year ABRAXANE net sales of between $125 - $140 million. ... - Yahoo! News (press release)

At the Crossroads of Medicine and Money Feb 26, 2006
And it led him, with early financial help from his TV-actress wife and from former auto mogul Lee Iacocca, to develop Abraxane, the first anti-cancer agent on ... - Los Angeles Times,

American Pharmaceutical Partners Reports Record 2005 Sales and Net ... Feb 17, 2006
...to $23.4 million, or $0.32 per diluted share, or $0.38 per diluted share excluding the impact of severance and merger costs of $7.3 million; * ABRAXANE(R) net ... - MSN Money

American Pharmaceutical Partners Reports Record 2005 Sales and Net ... Feb 17, 2006
...of 2004. Fourth quarter 2005 results included net sales of ABRAXANE(R), launched in February 2005, of $47.5 million. Impacted by ... - International News Service,

American Pharma net up; gets OK for generic ovarian cancer drug Feb 17, 2006
...quarter sales climbed to $144.8 million from $122.6 million a year ago, helped by $47.5 million in net sales of breast-cancer treatment Abraxane, which was ... - MarketWatch

[ Business Briefs ] Feb 20, 2006
The drug maker said its earnings benefited from the launch of cancer drug Abraxane and its upgraded Melrose Park facility returning to full operation, offset ... - International News Service,

Metastatic Melanoma Responds to Taxol® and Paraplatin® Feb 16, 2006
However, Abraxane has been reported to have single agent activity suggesting a role for taxanes. Abraxane is an albumin-bound paclitaxel ... - Cancer Consultants (press release),

American Pharma 4Q Earnings Up 7 Percent Feb 17, 2006
...share. Sales rose 18 percent to $144.8 million from $122.6 million, helped by $47.5 million in sales of cancer drug Abraxane. Excluding ... - Houston Chronicle,

American Pharma backs drug revenue view Feb 9, 2006
...on Thursday. The company said it continues to expect sales of its Abraxane drug to range from $125 million to $140 million. The ... - BusinessWeek

UPDATE 3-Australia's Mayne tops forecasts, shares surge Feb 21, 2006
...(APPX.O: Quote, Profile, Research), which is set to merge with American BioScience Inc., giving it global control over sales of breast cancer drug Abraxane. ... - Reuters

The Real Story: Less Is Not More Feb 21, 2006
The company also failed to assuage concerns of channel-stuffing prior to a year-end price increase for cancer fighter Abraxane. - TheStreet.com

American Pharmaceutical Partners and American BioScience Announce ... Feb 14, 2006
Abraxis Oncology, expected to be led by Carlo Montagner, will focus on the global commercialization of ABRAXANE(R) (paclitaxel protein-bound particles for ... - PR Newswire (press release),

American Pharmaceutical Partners Receives Two FDA Approvals for ... Feb 16, 2006
Oncology, the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(R) for ... - International News Service,

(PRN) - Ingen Technologies, Inc. Secure Balance(TM) Reaches the ... Feb 9, 2006
...(PRN) - American Pharmaceutical Partners Reiterates 2005 ABRAXANE Revenue Guidance; Schedules Fourth Quarter and Full Year Earnings Release and Conference Call ... - Bolsamania.com,

American Pharma Backs Drug Revenue View 09 Feb 2006
...on Thursday. The company said it continues to expect sales of its Abraxane drug to range from $125 million to $140 million. The ... - Houston Chronicle,

Carlo Montagner to Be Named President of Abraxis Oncology Upon ... Jan 25, 2006
...- Former Head of Schering AG Oncology Global Business and Sanofi-Aventis Oncology Will Lead ABRAXANE(R) Worldwide Commercialization Program Upon Completion of ... - PR Newswire (press release),

Carlo Montagner to Be Named President of Abraxis Oncology Upon ... Jan 25, 2006
Mr. Montagner will serve as president of American BioScience's commercial development division to lead the worldwide commercialization efforts for ABRAXANE. ... - PharmaLive.com (press release),

American Pharmaceutical Partners to Present at the Merrill Lynch ... Feb 2, 2006
Oncology, the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(R) for ... - PR Newswire (press release),

- Presentation Was Made by the Honorable Rudolph Giuliani - Jan 27, 2006
Dr. Soon-Shiong was honored for his work in developing the first nanoparticle chemotherapy technology, ABRAXANE(R) (paclitaxel protein-bound particles for ... - PR Newswire (press release),

Going Broke To Stay Alive Jan 23, 2006
He is now trying to survive on a combination of Herceptin, Avastin, and Abraxane, a new chemotherapy from American Pharmaceutical Partners Inc. ... - BusinessWeek

Novel Strategies for Treating Lung Cancer: Chemotherapy Jan 24, 2006
2005; New York, NY. Rizvi NA. Phase 1/2 study of ABI-007 (Abraxane) in chemotherapy naive advanced NSCLC. Program and abstracts of ... - Medscape (subscription)

Biotechnology Industry Ends 2005 with Breakthrough Product ... Jan 18, 2006
...also received approval on first-in-class product Abraxane for the treatment of breast cancer after failure of combination therapy for metastatic disease or ... - Yahoo! News (press release)

(PRN) Positive ABRAXANE(R) Data in Early-Stage (Adjuvant) Breast ... Dec 9, 2005
...observed with dose-dense combination therapy in early-stage breast cancer patients who received AC (Adriamycin(R) plus Cytoxan(R)) followed by ABRAXANE(R) as ... - Houston Chronicle,

Abraxane™ Effective for Initial Treatment of Metastatic Non ... Nov 11, 2005
Researchers from Memorial Sloan-Kettering Cancer Center have reported that Abraxane (albumin-bound paclitaxel) appears to be effective and well tolerated as ... - Cancer Consultants (press release),

Abraxane™ Shows Significant Activity for the Treatment of ... Nov 11, 2005
Researchers from the University of Arizona have reported that Abraxane (albumin-bound paclitaxel) has significant activity for the treatment of patients with ... - Cancer Consultants (press release),

Taiho Pharmaceutical Licensed to Develop and Sell ABRAXANE Anti ... Nov 21, 2005
Tokyo (JCN) Nov 21, 2005- Taiho Pharmaceutical announced on November 16 that it has signed a licensing agreement with American BioScience for ABRAXANE, an anti ... - Japan Corporate News (press release),

American Pharmaceutical Partners to Merge with Parent Company ... Nov 28, 2005
...- ABI's nab(TM) Technology Facilitates Efficient, Rapid Development of New Drugs with 6 INDs in development; ABRAXANE(R) in 74 Company and Investigator ... - PR Newswire (press release),

American Pharmaceutical Partners to Merge with Parent Company ... Nov 28, 2005
ABI will immediately bring to the new company 50% of the profits from North American sales of ABRAXANE(R) as well as the marketing rights for the rest of the ... - PharmaLive.com (press release),

Other News To Note Dec 9, 2005
...were observed with dose-dense combination therapy in early stage breast cancer patients who received Adriamycin plus Cytoxan followed by Abraxane as adjuvant ... - TMCnet

ABI In $4B Merger With APP To Create Abraxis BioScience Nov 28, 2005
The merger is intended to consolidate sales and marketing rights to the breast cancer drug, Abraxane, and bring together APP's commercial and manufacturing ... - BioWorld Online (subscription),

Drug firms get together Nov 29, 2005
...allow management to eliminate hurdles and more effectively make and sell new products as they come on the market, such as the injectable cancer drug Abraxane. ... - Chicago Tribune,

American Pharmaceutical to buy holder Nov 28, 2005
...the Nasdaq. The deal will centralize sales of breast cancer drug Abraxane, which gained US regulatory approval this year. The transaction ... - Washington Post,

American Pharmaceutical to merge Nov 28, 2005
The all-stock deal, which will combine the companies under the new name Abraxis BioScience, will centralize sales of breast cancer drug Abraxane, which gained ... - Reuters

Biotech Buyout Draws Rebuke Nov 29, 2005
The two companies already split profit from sales of Abraxane, a breast cancer drug that received Food and Drug Administration approval this year. ... - Los Angeles Times,

Biotech firms to merge in $4b deal Nov 29, 2005
The combination allows the new company to have the worldwide rights for Abraxane, a chemotherapy treatment, which may eventually generate more than $1 billion ... - Boston Globe,

Am Pharm Partners to merge with parent Nov 28, 2005
The newly-formed company will have global ownership of cancer drug Abraxane, currently being studied in 74 clinical trials, APP said. ... - United Press International

(PRN) - MathStar Announces New Management Team and Addition of ... Dec 9, 2005
...[+]. (PRN) - Positive ABRAXANE(R) Data in Early-Stage (Adjuvant) Breast Cancer and Solid Tumors Reported at San Antonio Breast Cancer Symposium ... [+. ... - Bolsamania.com,

Albumin-bound Paclitaxel, Clofarabine and Erlotinib Expand ... Nov 14, 2005
One the most newsworthy developments is the availability of the nanoparticle albumin-bound paclitaxel -- Abraxane -- for treatment of patients with refractory ... - DG News

Delphi will delay contract request Nov 28, 2005
...$500 million. The company will be named Abraxis BioScience and will have worldwide rights to Abraxane, a cancer treatment drug. - Minneapolis Star Tribune (subscription),

American Pharma to merge with parent Nov 28, 2005
...to close during the first half of 2006, the merger will give rise to a "fully integrated, global biopharmaceutical company," with oncology drug Abraxane as its ... - MarketWatch

American Pharmaceutical Partners to buy biggest shareholder for US ... Nov 28, 2005
The new company will be named Abraxis BioScience and will have worldwide rights to cancer treatment Abraxane, which is marketed in the United States for ... - CBC News,

American Pharmaceutical to merge with parent Nov 28, 2005
American BioScience will contribute its half of the profits from North American sales of breast cancer drug Abraxane, as well as its pipeline of oncology and ... - Crain's Chicago Business,

American Pharmaceutical Partners to buy biggest shareholder Nov 28, 2005
The new company will be named Abraxis Bio-Science and will have worldwide rights to Abraxane -- a cancer treatment being marketed in the United States. - KWQC-TV,

American Pharmaceutical to merge with American BioScience Nov 28, 2005
...million. The entity would have worldwide rights for the breast cancer drug, Abraxane, which was approved in the US earlier this year. ... - New Ratings

AMERICAN PHARMACEUTICAL MERGES WITH OWNER Nov 28, 2005
...companies said Monday. The new company will own global rights to Abraxane, a nanoparticle-based breast cancer drug. Also, it will ... - Small Times

American Pharmaceutical to merge with parent company Nov 28, 2005
28 Nov 2005, 15:37 GMT - The new company will market and develop Abraxane, which is approved in the US for metastatic breast cancer and is being developed for ... - Pharmaceutical Business Review

Pharmaceutical company says it will buy largest shareholder Nov 29, 2005
The new company will be named Abraxis BioScience and will have worldwide rights to Abraxane, which is marketed in the United States for metastatic breast ... - TheNewsTribune.com (subscription),

NCCN Announces Two New Breast Cancer Resources Dec 6, 2005
For metastatic disease, new regimens including paclitaxel (Taxol) plus bevacizumab (Avastin) and albumin-bound paclitaxel (Abraxane) were added to the existing ... - Business Wire (press release),

Stocks Fall on Merck Cuts, Retail Sales Nov 28, 2005
Combined revenue will total more than $500 million a year from sales of cancer treatment Abraxane. American Pharmaceutical sank $5.07 to $42.54. ... - CBS News

American Pharmaceutical Merges With Holder Nov 28, 2005
The centerpiece of the companies' merger is the breast-cancer drug Abraxane, a branded product that was approved by the Food and Drug Administration earlier in ... - TheStreet.com

American Pharm. stock takes hit after purchase Nov 29, 2005
Soon-Shiong disagreed and said the "best way to strategically develop" the company's key breast cancer drug, Abraxane; the technology platform, and pipeline ... - Chicago Sun-Times,

Investment firm agrees to settlement worth $100 million Nov 29, 2005
The company, to be named Abraxis BioScience, will have worldwide rights to cancer treatment Abraxane, which is marketed in the United States for metastatic ... - Indianapolis Star,

American Pharmaceutical merges with owner Nov 28, 2005
The new company will own global rights to Abraxane, a breast cancer drug in clinical trials for possible treatment of other types of cancer. ... - United Press International

American Pharma combines with BioScience Nov 28, 2005
The new group will have a combined marker value of $7.5bn on a fully diluted basis and will have worldwide rights to cancer treatment Abraxane. - ShareCast,

American Pharmaceutical buying American BioScience Nov 28, 2005
Abraxis Bioscience will have global rights to Abraxane, a cancer treatment marketed in the United States for metastatic breast cancer, and being developed for ... - Bizjournals.com,

Business Digest Nov 29, 2005
...revenue $500 million. The new company will be named Abraxis BioScience and will have worldwide rights to cancer treatment Abraxane. - Canada East,

(PRN) - Following Is a Test Release ... [+] Nov 28, 2005
...with Parent Company, American Bioscience, Creating Abraxis Bioscience, a Fully-Integrated Biopharmaceutical Company with Global Ownership of ABRAXANE(R), nab ... - Bolsamania.com,

American Pharmaceutical Partners Receives FDA Approval for ... Nov 30, 2005
...the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(TM), recently ... - PR Newswire (press release),

Business Briefing Nov 29, 2005
The combination allows the new company to have the worldwide rights for Abraxane, a chemotherapy treatment that won US approval in January for use in women ... - Sun-Sentinel.com,

TECH TICKER Nov 29, 2005
...than $500 million. The new company will be named Abraxis BioScience and will have rights to cancer treatment Abraxane. Patrick Soon ... - San Jose Mercury News,

(PRN) - Motorola Showcases Seamless Mobility Vision at 3G World ... Nov 15, 2005
...[+]. (PRN) - American BioScience Licenses ABRAXANE(TM) to Taiho Pharmaceutical Co., Ltd., one of The Largest Oncology Companies in Japan ... [+. ... - Bolsamania.com,

Superiority of Abraxane® to Taxol® in Breast Cancer Confirmed Oct 6, 2005
Researchers involved in a multi-center randomized international trial have reported that Abraxane (ABI-007), an albumin-bound paclitaxel, was more effective ... - Cancer Consultants (press release),

Sonus, Schering In Tocosol Paclitaxel Deal Worth $168M Oct 18, 2005
The administration time is shorter than that of another paclitaxel product, Abraxane, which gained FDA approval in January for breast cancer. ... - BioWorld Online (subscription),

American Pharmaceutical Partners to Report 2005 Third Quarter ... Oct 20, 2005
...the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(TM), recently ... - PR Newswire (press release),

Midwest large cap life science group strengthening in the third ... Oct 3, 2005
American Pharmaceutical Partners has also been on a roll ever since new CEO Al Heller took charge and its new cancer drug Abraxane was approved by the FDA and ... - WTN News,

Sonus starts key trial for breast cancer drug Sep 29, 2005
...like Taxol and French pharmaceutical giant Sanofi-Aventis' Taxotere but also from American Pharmaceutical Partners' recently approved Abraxane, and possibly ... - Seattle Times,

Superiority of Abraxane® to Taxol® in Breast Cancer Confirmed Oct 3, 2005
...to a recent early on-line publication in the Journal of Clinical Oncology, results from a large phase III trial have confirmed that Abraxane® (albumin-bound ... - Cancer Consultants (press release),

American Pharmaceutical Partners Provides Update on Its Melrose ... Sep 26, 2005
...- Full Production Expected to Resume in November 2005; ABRAXANE(TM) Sales Not Anticipated to be Affected - SCHAUMBURG, Ill., Sept. ... - PR Newswire (press release),

American Pharmaceutical Partners Provides Update on Its Melrose ... Sep 26, 2005
The company reiterated that sales of the proprietary product ABRAXANE(TM), which also is produced at the Melrose Park facility, are not anticipated to be ... - Yahoo! News (press release)

After Two Decades, New Hope For Drugs That Target Cancer Sep 9, 2005
One nanotechnology product in use is Abraxane from American BioScience, a unit of American Pharmaceutical Partners. (APPX). Abraxane ... - Investor's Business Daily (subscription)

After Two Decades, New Hope For Drugs That Target Cancer 09 Sep 2005
One nanotechnology product in use is Abraxane from American BioScience, a unit of American Pharmaceutical Partners. (APPX). Abraxane ... - Investor's Business Daily (subscription)

Market Strategies Announces 'HALO' Effect of ASCO 2005 Still ... Sep 8, 2005
Physicians also indicated that some of the excitement they felt about ABRAXANE has dissipated as they returned to the realities of their practice. ... - PR Newswire (press release),

Abraxane™ Active in Previously Treated and Untreated Women with ... Sep 2, 2005
Researchers from the MD Anderson Cancer Center have reported that Abraxane (ABI-007), a nanoparticle, albumin-bound paclitaxel, is active in women with ... - Cancer Consultants (press release),

Abraxane™ Highly Effective in Metastatic Breast Cancer Sep 1, 2005
...paclitaxel. Abraxane is a new form of paclitaxel that is bound with albumin, a type of protein normally found in the human body. ... - Cancer Consultants (press release),

American Pharmaceutical Partners Reports on Melrose Park, Il ... Aug 25, 2005
...* Upgrade of Melrose Park, Illinois Plant to Take Longer Than Expected * Availability of ABRAXANE(TM) not Impacted * Delay Anticipated to Affect a Limited ... - PR Newswire (press release),

American Pharmaceutical Partners Reports on Melrose Park, Il ... Aug 25, 2005
Sales of the proprietary product ABRAXANE(TM), which also is produced at the Melrose Park facility, are not anticipated to be impacted by the delay. ... - Yahoo News (press release)

American Pharmaceutical Partners Launches Enhanced Corporate Web ... Aug 30, 2005
The Web site provides related links to APP's proprietary drug division, Abraxis Oncology (http://www.abraxisoncology.com) and ABRAXANE(TM) (http://www.abraxane ... - PR Newswire (press release),

American Pharmaceutical Partners to Present at The Bear Stearns ... Sep 6, 2005
...the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(TM), recently ... - PR Newswire (press release),

Mayne says demerger plans on track Aug 23, 2005
Mr James said the introduction of a competing drug, American Pharmaceutical Partners Inc's Abraxane, had to date not had a noticeable impact on paclitaxel ... - Seven.com.au,

Lopsided Base May Be Indication That Stock's Breakout Won't Last Aug 10, 2005
...sliding. In October, a Barron's article cited concerns over clinical trial results for the firm's cancer treatment, Abraxane. Near ... - Investor's Business Daily (subscription)